Variable | RR | 95% CI | Total | PSA relapse | % | p |
---|---|---|---|---|---|---|
Stage | 0.058 | |||||
T1a/T1b/T1c | 1.00 | 73 | 5 | 6.8 | ||
T2a/T2b/T2c | 2.91 | 1.04 – 8.17 | 62 | 13 | 21.0 | |
T3a/T3b | 6.02 | 0.67 – 54.22 | 5 | 1 | 20.0 | |
Gleason score | 0.774 | |||||
≤ 6 | 1.00 | 53 | 6 | 11.3 | ||
7 | 1.08 | 0.37 – 3.12 | 56 | 8 | 14.3 | |
8 – 10 | 1.50 | 0.46 – 4.94 | 31 | 5 | 16.1 | |
PSA | 0.493 | |||||
< 10 | 1.00 | 106 | 13 | 12.3 | ||
10 – 19.9 | 1.74 | 0.61 – 4.97 | 28 | 5 | 17.9 | |
≥ 20 | 2.07 | 0.27 – 16.21 | 6 | 1 | 16.7 | |
NCCN Risk Group | 0.331 | |||||
Low | 1.00 | 36 | 3 | 8.3 | ||
Intermediate | 1.61 | 0.43 – 5.94 | 64 | 9 | 14.1 | |
High | 2.62 | 0.67 – 10.16 | 40 | 7 | 17.5 | |
Age (years) | 0.324 | |||||
< 60 | 1.00 | 21 | 2 | 9.5 | ||
≥ 60 e < 75 | 2.15 | 0.48 – 9.49 | 86 | 15 | 17.4 | |
≥ 75 | 0.89 | 0.12 – 6.53 | 33 | 2 | 6.1 | |
Total | 140 | 19 | 13.6 |